Security Investigation
Zoetis, Inc. (NYSE: ZTS)
60 Days left to seek lead plaintiff status.
Contact a Lawyer Now
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until July 27, 2026 to file lead plaintiff applications in a securities class action lawsuit against Zoetis, Inc. (Zoetis or the Company) (NYSE: ZTS).
Zoetis and certain of its executives are charged with failing to disclose material information during the Class Period concerning the growth, competitive positioning, market share, and veterinarian adoption of key products within the Companion Animal segment, violating federal securities laws.
The alleged false and misleading statements and/or omissions include, but are not limited to, that: (i) veterinarian prescription growth and adoption of the Company’s canine pain treatment, Librela, were stalling as clinicians became more cautious due to FDA safety warnings of serious neurological complications; (ii) Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (iii) the Company’s dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment.
If you purchased securities of Zoetis and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or fill out the form on this page.
The case is City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis, Inc., No. 26-cv-04401.